



Correction to: Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination

Tohru Inaba¹ · Keita Okumura² · Chika Maekura³ · Ayako Muramatsu³ · Tsutomu Kobayashi³ · Junya Kuroda³ · Yoko Nukui¹

Published online: 5 May 2022
© Japanese Society of Hematology 2022

Correction to: International Journal of Hematology
<https://doi.org/10.1007/s12185-022-03349-1>

In the original publication of the article, the table related to case study was missing. The case study table is given in this correction.

The original article can be found online at <https://doi.org/10.1007/s12185-022-03349-1>.

✉ Tohru Inaba
inaba178@koto.kpu-m.ac.jp

¹ Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

² Faculty of Clinical Laboratory, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

³ Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Case	Disease	CD20 MoAb ^{*1}	SARS-CoV2		Anti-SARS-CoV-2 Antibodies (AU/mL) ^{*2}					Serum IgG (mg/dL) ^{*3}	Time ^{*4}
			Infection	Vaccine	IgG-N	IgM-N	IgG-S1	IgM-S1	Nab		
Case 1	FL	37	+	-	n.t. ^{*5}	n.t	n.t	n.t	0.68	563	+2w
					0.27	0.14	0.39	0.21	3.48	441	+4w
					0.19	0.33	0.37	0.23	1.44	183	+10w
Case 2	FL	1	+	-	9.46	0.82	0.47	0.48	2.37	685	+2w
					235.22	29.82	16.79	2.23	21.21	576	+4w
Case 3	FL	12	+	+	0.32	1.12	7.09	594.44	140.16	492	+2w
					0.32	0.95	8.01	578.75	213.00	461	+4w
Case 4	Healthy	0	-	+	0.53	0.16	9.78	0.63	5.88	1,290	+2w
					0.50	0.17	2145.96	18.97	2836.82	1,291	+4w

*1: Number of anti-CD20 monoclonal antibody-containing chemotherapy sessions administered in each case

*2: Bold numbers with underline mean positive antibody titers (> 10 AU/mL)

*3: Reference interval of serum IgG is 861–1747 mg/dL in our hospital

*4: In Cases 1–3, time from the onset of SARS-CoV2 infection. In Case 4, time from the initial vaccination

*5: n.t.: not tested

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.